



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 September 2021
EMA/CAT/458500/2021
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of CAT written procedure 11-13 August 2021

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	4
1.1.	Adoption of agenda	4
1.2.	Adoption of the minutes	4
2.	Evaluation of ATMPs	4
2.1.	Opinions	4
2.2.	Oral explanations	4
2.3.	Day 180 list of outstanding issues	4
2.4.	Day 120 list of questions	4
2.5.	Day 80 assessment reports	4
2.6.	Update on ongoing initial applications.....	4
2.6.1.	Lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - EMEA/H/C/004731	4
2.7.	New applications	5
2.8.	Withdrawal of initial marketing authorisation application	5
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	5
2.10.	GMP and GCP inspections requests.....	5
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	5
2.12.	Extension applications.....	5
2.13.	Other Post-Authorisation Activities	5
2.13.1.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/016	5
2.13.2.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/017	5
3.	Certification of ATMPs	6
3.1.	Opinion.....	6
3.2.	Day 60 Evaluation Reports.....	6
3.3.	New Applications.....	6
4.	Scientific Recommendation on Classification of ATMPs	6
4.1.	New requests – Appointment of CAT Coordinator	6
4.1.1.	Point-of-care skin cell isolation kit.....	6
4.1.2.	Optimised DNA encoding the sequence of interest COL7A1	6
4.1.3.	Adipose derived Mesenchymal Stem/Stromal Cells.....	7
4.1.4.	Recombinant adeno-associated virus serotype HSC 15 (rAAVHSC15) expressing human iduronate-2-sulfatase (hIDS)	7
4.2.	Day 30 ATMP scientific recommendation	7
4.3.	Day 60 revised scientific recommendation (following list of questions)	7
4.4.	Finalisation of procedure	7

4.4.1.	Autologous population of selected renal cells (SRC)	7
4.4.2.	Autologous adipose mesenchymal stem cells (MSCs).....	7
4.4.3.	Allogeneic natural killer cells armed with anti-CD20 monoclonal antibody	7
4.4.4.	Recombinant serotype 9 adeno-associated virus encoding a codon-optimised human galactosylceramidase transgene [ssAAV9/CBA-hsaGALCopt2-SV40p (AAV9-hGALC)]	8
4.4.5.	Minimally manipulated autologous pancreatic islets.....	8
4.4.6.	HEK293 cells transfected with a lentiviral vector to express the tumour-specific antigen, WT1 and the antigen presenting molecule, cluster of differentiation 1d (CD1d).....	8
4.4.7.	Ribonucleoprotein (RNP), a complex of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas 9 and sgRNA, delivered by a novel synthetic non-viral vector, for the excision of exon 80 of the human COL7A1 gene	8
4.4.8.	Live human mesenchymal stem cells derived from allogeneic Wharton’s jelly	8
4.4.9.	Live human mesenchymal stem cells derived from allogeneic Wharton’s jelly	8
4.4.10.	Live human mesenchymal stem cells derived from allogeneic Wharton’s jelly	9
4.5.	Follow-up and guidance.....	9
5.	Scientific Advice	9
5.1.	New requests - appointment of CAT Rapporteurs	9
5.2.	Procedures with a discussion meeting with the applicant	9
5.3.	Finalisation of SA procedures	9
6.	Pre-Authorisation Activities	9
6.1.	Paediatric investigation plans.....	9
6.2.	ITF briefing meetings in the field of ATMPs	9
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	9
7.	Organisational, regulatory and methodological matters	10
7.1.	Mandate and organisation of the CAT	10
7.2.	Coordination with EMA Scientific Committees.....	10
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	10
7.4.	Cooperation with the EU regulatory network.....	10
7.5.	Cooperation with international regulators.....	10
7.6.	CAT work plan	10
7.7.	Planning and reporting	10
7.8.	Others	10
8.	Any other business	10
9.	Explanatory notes	11

1. Introduction

1.1. Adoption of agenda

The CAT agenda for 11-13 August 2021 meeting was adopted

1.2. Adoption of the minutes

The CAT minutes from the 14-16 July 2021 meeting will be adopted at the September CAT plenary on 08-10 September 2021.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - EMEA/H/C/004731

Bristol-Myers Squibb Pharma EEIG; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: MAA's request (dated 27.07.2021) for a clock-stop extension.

Action: for adoption

List of Questions (LoQ) adopted on 06.11.2020. List of Outstanding Issues (LoOI) adopted on 16.04.2021

The clock stop extension was agreed and the revised timetable was adopted.

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/016

Novartis Gene Therapies EU Limited

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Quality

Action: for adoption

The report was adopted.

2.13.2. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/017

Novartis Gene Therapies EU Limited

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Non-clinical: the MAH is formally providing the Agency with discussion surrounding inconsistencies found in data for a preclinical pharmacology study in SMNΔ7 mice performed in 2008-2010 at Nationwide Children's Hospital.

Action: for adoption

The report was adopted.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

Next deadline for submission of new requests is 26 August 2021. These will appear in the CAT Agenda 08-10 September 2021.

Timetable:

-Start of the procedure:	13.08.2021
-EMA Coordinator's draft report:	27.08.2021
-CAT Coordinator's comments:	01.09.2021
-Revised scientific recommendation:	03.09.2021
-CAT's discussion of scientific recommendation:	10.09.2021

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Point-of-care skin cell isolation kit

Intended for skin regeneration after burns, skin trauma, invasive surgery

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Optimised DNA encoding the sequence of interest COL7A1

Intended for the treatment of dystrophic epidermolysis bullosa (DEB)

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Adipose derived Mesenchymal Stem/Stromal Cells

Intended for the treatment of amyotrophic lateral sclerosis

EMA Coordinator: Patrick Celis

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.4. Recombinant adeno-associated virus serotype HSC 15 (rAAVHSC15) expressing human iduronate-2-sulfatase (hIDS)

Intended for the treatment of mucopolysaccharidosis type II (known as Hunter syndrome)

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

No items

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous population of selected renal cells (SRC)

Intended for the treatment of chronic kidney disease (CKD)

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.2. Autologous adipose mesenchymal stem cells (MSCs)

Indicated for cartilage defects of degenerative origin and for the treatment of osteoarthritis

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.3. Allogeneic natural killer cells armed with anti-CD20 monoclonal antibody

Intended for the treatment of B-Cell Non-Hodgkin lymphoma

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.4. Recombinant serotype 9 adeno-associated virus encoding a codon-optimised human galactosylceramidase transgene [ssAAV9/CBA-hsaGALCopt2-SV40p (AAV9-hGALC)]

Intended for the treatment of Krabbe disease

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.5. Minimally manipulated autologous pancreatic islets

Intended for the treatment of chronic pancreatitis and recurrent acute pancreatitis immediately following pancreatectomy

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.6. HEK293 cells transfected with a lentiviral vector to express the tumour-specific antigen, WT1 and the antigen presenting molecule, cluster of differentiation 1d (CD1d)

Intended for the treatment of WT1-expressing tumours

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.7. Ribonucleoprotein (RNP), a complex of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas 9 and sgRNA, delivered by a novel synthetic non-viral vector, for the excision of exon 80 of the human COL7A1 gene

Intended for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.8. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of rheumatoid arthritis, unspecified

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.9. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of systemic lupus erythematosus, unspecified

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.4.10. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of systemic sclerosis, unspecified

Scope: The European Commission raised no comments; ATMP scientific recommendation

Action: for information

The information was noted. The finalised classification report will be sent to the applicant.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

No items

5.2. Procedures with a discussion meeting with the applicant

No items

5.3. Finalisation of SA procedures

No items

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

No items

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

No items

7.6. CAT work plan

No items

7.7. Planning and reporting

No items

7.8. Others

No items

8. Any other business

No items

Date of next CAT meeting:

08-10/09/2021

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines
 QRD: Quality review of documents
 RMP: Risk Management Plan
 RP: Reflection paper
 RSI: Request for supplementary information
 SAs: Scientific Advices
 SAG-O: Scientific Advisory Group Oncology
 SAWP: Scientific Advice Working Party
 SR: Summary Report
 SWP: Safety Working Party
 SME: Small and medium size enterprises
 SmPC: Summary of Products Characteristics
 TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/